Beta-glucocerebrosidase en es it fr

Beta-glucocerebrosidase Brand names, Beta-glucocerebrosidase Analogs

Beta-glucocerebrosidase Brand Names Mixture

  • No information avaliable

Beta-glucocerebrosidase Chemical_Formula

C2532H3854N672O711S16

Beta-glucocerebrosidase RX_link

http://www.rxlist.com/cgi/generic2/imiglucerase.htm

Beta-glucocerebrosidase fda sheet

Beta-glucocerebrosidase msds (material safety sheet)

Beta-glucocerebrosidase Synthesis Reference

No information avaliable

Beta-glucocerebrosidase Molecular Weight

55597.4

Beta-glucocerebrosidase Melting Point

No information avaliable

Beta-glucocerebrosidase H2O Solubility

No information avaliable

Beta-glucocerebrosidase State

Liquid

Beta-glucocerebrosidase LogP

-0.168

Beta-glucocerebrosidase Dosage Forms

Powder for solution; Solution (IV injection)

Beta-glucocerebrosidase Indication

For the treatment of Gaucher's disease (deficiency in glucocerebrosidase)

Beta-glucocerebrosidase Pharmacology

Gaucher disease is characterized by a functional deficiency in Beta-glucocerebrosidase enzymatic activity and the resultant accumulation of lipid glucocerebroside in tissue macrophages which become engorged and are termed Gaucher cells. Gaucher cells are typically found in liver, spleen and bone marrow. This can lead to an enlarged spleen and liver (hepatosplenomegaly). Secondary hematologic sequelae include severe anemia and thrombocytopenia. Injections of imiglucerase into Gaucher disease patients leads to elevated serum levels of the enzyme and reduction in the accumulation of glucocerebroside leading to reduced anemia and thrombocytopenia, reduced spleen and liver size, and decreased cachexia

Beta-glucocerebrosidase Absorption

No information avaliable

Beta-glucocerebrosidase side effects and Toxicity

No information avaliable

Beta-glucocerebrosidase Patient Information

No information avaliable

Beta-glucocerebrosidase Organisms Affected

Humans and other mammals